Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition

Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition

Direct Oral Anticoagulants (DOACs) have revolutionized the treatment of thromboembolic disorders, offering targeted, effective, and safer alternatives to traditional anticoagulants like heparins and vitamin K antagonists (VKAs). Despite their benefits, DOACs have drawbacks, including an increased ri...

Full description

Bibliographic Details
Main Authors: Hisham A. Badreldin, Nada Alsuhebany, Mohammed Alzahrani, Abdulmajeed M. Alshehri, Maha Aldoughaim, Saleh Alqifari, Omar Yassin, Lama Alfehaid, Tariq Alqahtani
Format: Article
Language:English
Published: Elsevier 2024-01-01
Series:Current Research in Pharmacology and Drug Discovery
Subjects:
Thromboembolic disorders
Atrial fibrillation
Novel Anticoagulant
Abelacimab
Online Access:http://www.sciencedirect.com/science/article/pii/S2590257124000063

Similar Items

Similar Items